Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, USA; and Integrative Life Sciences PhD Program, Virginia Commonwealth University, USA.
Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, USA; and Department of Psychiatry, Virginia Commonwealth University, USA.
Br J Psychiatry. 2023 Jul;223(1):301-308. doi: 10.1192/bjp.2022.179.
Psychotic disorders and schizotypal traits aggregate in the relatives of probands with schizophrenia. It is currently unclear how variability in symptom dimensions in schizophrenia probands and their relatives is associated with polygenic liability to psychiatric disorders.
To investigate whether polygenic risk scores (PRSs) can predict symptom dimensions in members of multiplex families with schizophrenia.
The largest genome-wide data-sets for schizophrenia, bipolar disorder and major depressive disorder were used to construct PRSs in 861 participants from the Irish Study of High-Density Multiplex Schizophrenia Families. Symptom dimensions were derived using the Operational Criteria Checklist for Psychotic Disorders in participants with a history of a psychotic episode, and the Structured Interview for Schizotypy in participants without a history of a psychotic episode. Mixed-effects linear regression models were used to assess the relationship between PRS and symptom dimensions across the psychosis spectrum.
Schizophrenia PRS is significantly associated with the negative/disorganised symptom dimension in participants with a history of a psychotic episode ( = 2.31 × 10) and negative dimension in participants without a history of a psychotic episode ( = 1.42 × 10). Bipolar disorder PRS is significantly associated with the manic symptom dimension in participants with a history of a psychotic episode ( = 3.70 × 10). No association with major depressive disorder PRS was observed.
Polygenic liability to schizophrenia is associated with higher negative/disorganised symptoms in participants with a history of a psychotic episode and negative symptoms in participants without a history of a psychotic episode in multiplex families with schizophrenia. These results provide genetic evidence in support of the spectrum model of schizophrenia, and support the view that negative and disorganised symptoms may have greater genetic basis than positive symptoms, making them better indices of familial liability to schizophrenia.
精神分裂症患者的亲属中存在精神病和类精神分裂特质的聚集现象。目前尚不清楚精神分裂症患者及其亲属的症状维度变化与精神障碍的多基因易感性之间的关系。
研究多基因风险评分(PRS)是否可以预测精神分裂症多基因家族成员的症状维度。
使用最大的精神分裂症、双相情感障碍和重度抑郁症的全基因组数据集,在 861 名有精神病史的爱尔兰高密度多基因精神分裂症家族成员中构建 PRS。使用精神障碍操作性诊断标准检查表(对有精神病史的患者)和精神分裂症特质结构访谈表(对无精神病史的患者)得出症状维度。采用混合效应线性回归模型评估 PRS 与整个精神病谱中症状维度之间的关系。
精神分裂症 PRS 与有精神病史的患者的阴性/紊乱症状维度( = 2.31×10)和无精神病史的患者的阴性维度( = 1.42×10)显著相关。双相情感障碍 PRS 与有精神病史的患者的躁狂症状维度显著相关( = 3.70×10)。与重度抑郁症 PRS 无相关性。
精神分裂症的多基因易感性与有精神病史的患者的阴性/紊乱症状以及无精神病史的患者的阴性症状相关。这些结果为精神分裂症的谱系模型提供了遗传证据,支持了阴性和紊乱症状比阳性症状可能具有更大的遗传基础的观点,使其成为家族性精神分裂症易感性的更好指标。